Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations

Neurology

Volumn 47, Issue 5, 1996, Pages 1269-1277

  Baser, M E ^a,d   Mautner, V F ^b   Ragge, N K ^a   Nechiporuk, A ^a   Riccardi, V M ^c   Klein, J ^a   Sainz, J ^a   Pulst, S M ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allgemeines Krankenhaus Eilbek   (Germany)

^c Neurofibromatosis Institute   (United States)

^d Cedars Sinai Medical Center ^*  (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CATARACT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL PROTOCOL; FAMILY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC LINKAGE; GENETIC MARKER; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PEDIGREE; PRIORITY JOURNAL; RELATIVE;

EID: 0029989418     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.5.1269     Document Type: Article

References (59)

1. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618.
2. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-846.
3. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-461.
4. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
5. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521.
6. Knudson AG Jr. Mutation and cancer: statistical study of ret-inoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
7. Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. Arch Neurol 1994;51:201-207.
8. Harsh GR IV, MacCollin M, McKenna MJ, Nadol JB, Ojemann R, Short MP. Molecular genetic screening for children at risk of neurofibromatosis 2 [letter]. Arch Otolaryngol Head Neck Surg 1995;121:590-591.
9. Ruttledge MH, Narod SA, Dumanski JP, et al. Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology 1993;43:1753-1760.
10. Sainio M, Strachan T, Blomstedt G, et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995;45: 1314-1322.
11. MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J. DNA diagnosis of neurofibromatosis 2: altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA 1993;270:2316-2320.
12. Bijlsma EK, Merel P, Fleury P, et al. Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. Hum Genet 1995; 96:1-5.
13. Moyes PD. Familial bilateral acoustic neuroma affecting 14 members from four generations. J Neurosurg 1968;29:78-82.
14. Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 1993;33:92-96.
15. Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol 1995;120:634-641.
16. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-886.
17. Marineau C, Rouleau GA. Dinucleotide repeat polymorphism at the human CRYB2 gene locus. Nucleic Acids Res 1992;20: 1430.
18. Marineau C, Baron C, Delattre O, Zucman J, Thomas G, Rouleau GA. Dinucleotide repeat polymorphism at the D22S268 locus. Hum Mol Genet 1993;2:336.
19. Sainz J, Kim UJ, Simon M, Nechiporuk A, Pulst S. Microsatellite polymorphism in the neurofibromatosis 2 disease region at the locus D22S430. Hum Mol Genet 1993;2:2203.
20. Gyapay G, Morissette J, Vignal A, et al. The 1993-94 Généthon human genetic linkage map. Nat Genet 1994;7:246-339.
21. Porter JC, Ram KT, Puck JM. Twelve new polymorphic microsatellites on human chromosome 22. Genomics 1993;15:57-61.
22. Narod SA, Parry DM, Parboosingh J, et al. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet 1992;51:486-496.
23. Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multipoint linkage analysis in humans. Proc Natl Acad Sci USA 1984;81:3443-3446.
24. Evans DGR, Huson SM, Donnai D. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 1992;29:847-852.
25. Wang Z, Weber JL. Continuous linkage map of human chromosome 14 short tandem repeat polymorphisms. Genomics 1992;13:532-536.
26. Evans DGR, Bourn D, Wallace A, Ramsden RT, Mitchell JD, Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet 1995;32:470-474.
27. Egelhoff JC, Bates DJ, Ross JS, Rothner AD, Cohen BH. Spinal MR findings in neurofibromatosis types 1 and 2. AJNR Am J Neuroradiol 1992;13:1071-1077.
28. Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 1995;165:951-955.
29. Evans DGR, Ramsden R, Huson SM, Harris R, Lye R, King TT. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol 1993;107:401-406.
30. Baldwin D, King TT, Chevretton E, Morrison AW. Bilateral cerebellopontine angle tumors in neurofibromatosis type 2. J Neurosurg 1991;74:910-915.
31. Bederson JB, von Ammon K, Wichmann WW, Yasargil MG. Conservative management of patients with acoustic tumors. Neurosurgery 1991;28:646-651.
32. Nedzelski JM, Schessel DA, Pfleiderer A, Kassel EE, Rowed DW. Conservative management of acoustic neuromas. Otolaryngol Clin North Am 1992;25:691-705.
33. Strasnick B, Glasscock ME, Haynes D, McMenomey S, Minor LB. The natural history of untreated acoustic neuromas. Laryngoscope 1994;104:1115-1119.
34. Nadol JB Jr, Chiong CM, Ojemann RG, et al. Preservation of hearing and facial nerve function in resection of acoustic neuroma. Laryngoscope 1992;102:1153-1158.
35. Sobel RA, Wang Y. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993;52:106-113.
36. Jääskeläiene J, Paetau A, Pyykkö I, Blomstedt G, Palva T, Troupp H. Interface between the facial nerve and large acoustic neurinomas: immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg 1994;80:541-547.
37. Harper PS, Clarke A. Should we test children for "adult" genetic diseases? Lancet 1990;335:1205-1206.
38. Working Party of the Clinical Genetics Society. The genetic testing of children. J Med Genet 1994;57:1233-1241.
39. Wertz D, Fanos JH, Reilly PR. Genetic testing for children and adolescents: who decides? JAMA 1994;272:875-881.
40. American Society for Human Genetics/American College of Medical Genetics Report. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995;57:1233-1241.
41. Billings PR, Kohn MA, de Ceuvas M, Beckwith J, Alper JS, Notowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992;50:476-482.
42. Hudson KL, Rothenberg KH, Andrews LB, Kahn MJE, Collins FS. Genetic discrimination and health insurance: an urgent need for reform. Science 1995;270:391-393.
43. The Ad Hoc Committee on Genetic Testing/Insurance Issues. Background statement: genetic testing and insurance. Am J Hum Genet 1995;56:327-331.
44. Wertelecki W, Rouleau GA, Superneau DW, et al. Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med 1988;319:278-283.
45. Bourn D, Carter SA, Mason S, Evans DGR, Strachan T. Germ-line mutations in the neurofibromatosis 2 gene in multiple tumor types. Hum Mol Genet 1994;3:813-816.
46. Kluwe L, Pulst SM, Köppen J, Mautner VF. A 163-bp deletion at the C-terminus of the schwannomin gene associated with variable phenotypes of neurofibromatosis type 2. Hum Genet 1995;95:443-446.
47. Kluwe L, Mautner VF. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996;97:224-227.
48. Scoles D, Baser ME, Pulst SM. A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 1996;47:544-546.
49. Mautner VF, Baser ME, Kluwe L. Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet 1996;98:203-206.
50. Tees D, Lofchy N, Rutka J. Deafness, dysphagia and a middle ear mass in a patient with neurofibromatosis type 2. J Otolaryngol 1992;21:227-229.
51. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-184.
52. Papi L, de Vitis LR, Vitelli F, et al. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 1995;95:347-351.
53. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP. Familial meningioma is not allelic to neurofibromatosis type 2. Neurology 1993;43:2096-2098.
54. Baser ME, Ragge NK, Riccardi V, Janus T, Gantz B, Pulst S. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet 1996;64:563-567.
55. Kanter WR, Eldridge R. Evidence of a maternal effect in central neurofibromatosis. Lancet 1978;2:903.
56. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992;90: 41-54.
57. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993;5:274-277.
58. Boerkoel CF, Exelbert R, Nicastri C, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 1995;56:887-897.
59. Bourn D, Carter SA, Evans DGR, Goodship J, Coakham H, Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet 1994;55:69-73.